ChemoMetec A/S
The answer first
Does ChemoMetec beat the market?
No, ChemoMetec has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 72% of Nordic stocks
- Quality100
- Value6
- Trend81
No. 35 of 195 in healthcare
Expectations in the price
High expectations
For the share to return about 9% a year from today's price, the cash ChemoMetec keeps must grow about 22% a year for 10 years.
Max for seven days
Follow ChemoMetec with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about ChemoMetec
Your first answer is free, no account needed.
Do you own ChemoMetec, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with ChemoMetec and a few more. Free, no card.
Super Stock+44.6%In short
- ChemoMetec has fallen 7.4% over the past year, including dividends.
- Overall, ChemoMetec ranks better than 72% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 74.4%. The price is 35.6% below its peak now.
What do analysts think of ChemoMetec?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 72% of Nordic stocks.
No. 35 of 195 in healthcare
High A solid company: it earns well on its money and has healthy finances.
No. 1 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.01
- Asset turnoverSales divided by everything the company owns0.59
- Return on equityProfit divided by equity+27.8%
- Cash conversionOperating cash flow divided by profit1.04
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 159 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity16.0
- P/SPrice divided by sales22.7
- P/EPrice divided by earnings57.5
- P/CFPrice divided by operating cash flow55.2
The ranking is built on P/E, P/B and P/S.
High Tailwind in the share price: it has risen more than most over the last year.
No. 40 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months+42.5%
- 6 months+106.6%
- 9 months+72.7%
- 12 months−7.4%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own ChemoMetec
15 funds we follow own ChemoMetec. The share is how much of the fund the stock makes up.
- Norway2
- Sweden9
- Denmark4
- FIRST Veritas A SEKSweden · FIRST5.3%
- TIN Ny Teknik FSweden · TIN3.9%
- Didner & Gerge SmåbolagSweden · Didner2.0%
- Lannebo Hälsa och Ny Teknik ASweden · Lannebo1.9%
- Carnegie Småbolagsfond ASweden · Carnegie1.6%
- Handelsbanken Nordiska Småbol (A1 NOK)Sweden · Handelsbanken0.9%
- Protean Aktiesparfond Norden ASweden · Protean0.8%
- Kvartil Nordiska Småbolag+ Faktor ASweden · Kvartil0.5%
Show all 15
- BIX Danske Aktier Indeks ADenmark · BIX0.5%
- BIX Danske Aktier Indeks Akk ADenmark · BIX0.5%
- Danske Invest Danmark IndeksDenmark · Danske Invest0.5%
- Vibrand Norden ANorway · Vibrand0.4%
- Sydinv Indeks Danmark A DKKDenmark · Sydinvest0.3%
- Handelsbanken Norden Ind Crit (A1 NOK)Sweden · Handelsbanken0.2%
- KLP AksjeNorden IndeksNorway · KLP0.1%
From the funds' latest known holdings.
About ChemoMetec
ChemoMetec A/S is a company in healthcare, listed on Nasdaq Copenhagen. The share trades in DKK. It has around 170 employees.
ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company offers its solutions in the areas of cell and gene therapy, cancer and stem cell research, and development and manufacturing of pharmaceuticals, as well as production and quality control of animal semen, milk, and beer.


See the full analysis of ChemoMetec.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card